All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
Bookmark this article
During the 2023 Society of Hematologic Oncology (SOHO) Congress, the ALL Hub spoke to Maksim Mamonkin, Baylor College of Medicine, Houston, US. We asked, Is chimeric antigen receptor (CAR) T-cell therapy a safe and effective treatment option for relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoma.
Is CAR T-cell therapy a safe and effective treatment option for R/R T-ALL and lymphoma?
Firstly, Mamonkin discusses recent progress made in the development and evaluation of CAR T-cell therapies in T-ALL and lymphoma. He highlights several strategies that have yielded encouraging results, including autologous CD7-directed CAR T-cell therapies utilizing various methods, such as gene editing to prevent the risk of fratricide in China, CRISPR-based editing of anti-CD7 CAR T cells in the UK, and unedited CD7-directed CAR T cells in the US.
He goes on to mention challenges in the field, including preventing the risk of fratricide, reducing ablation of circulating endogenous CAR T cells, T-cell aplasia, and antigen escape. One alternative approach currently being investigated to overcome antigen escape is the use of different antigen targets, such as CD5-directed CAR T cells. Both CD7 and CD5-directed CAR T-cell therapies are paving the way in the treatment of R/R T-ALL.
Your opinion matters
Progress of targeted therapies and immunotherapies in T-ALL/LBL
Here, we summarize a review by Huang et al. on the progress of targeted therapies and immunotherapies in the treatment of patients with T-cell acute lymphoblastic leukemia.
WU-CART-007 receives orphan drug designation for T-ALL
On March 15, 2022, the allogeneic CD7-directed chimeric antigen receptor (CAR) T-cell product, WU-CART-007, was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) in...
Subscribe to get the best content related to ALL delivered to your inbox